Merck & Company, Inc. vs Regeneron Pharmaceuticals, Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and Regeneron Pharmaceuticals, Inc. (REGN) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Regeneron Pharmaceuticals, Inc. clearly outscores Merck & Company, Inc. on Q·Score (8.5 vs 6.9 out of 10), led by Health (9.7 vs 7) and Valuation (8.7 vs 6.4). Analyst consensus targets imply greater upside for REGN (+36.1%) than for MRK (+9.0%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 19% return on equity and 14% profit margins.
Clean balance sheet with low leverage (0.1× debt-to-equity).
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs REGN: which stock scores better overall?
Based on Q·Score, Regeneron Pharmaceuticals, Inc. (REGN) scores 8.5/10 versus Merck & Company, Inc. (MRK) at 6.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Growth (7.3/10 vs 6.2/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while Regeneron Pharmaceuticals, Inc. reports (19.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or REGN more attractively valued?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Valuation (8.7/10 vs 6.4/10). MRK trades at 12.4× P/E versus REGN at 11.4×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs REGN?
There are 27 analysts covering MRK with a consensus price target of $129.74, and 28 analysts covering REGN with a consensus target of $833.31. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Quality (8.8/10 vs 7.7/10). Net profit margin: MRK at 13.6%, REGN at 29.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Financial Health (9.7/10 vs 7/10). Market beta: MRK at 0.22, REGN at 0.24. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and REGN?
Merck & Company, Inc. (MRK) has a market capitalisation of $294.0B, while Regeneron Pharmaceuticals, Inc. (REGN) has a market cap of $64.2B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or REGN pay dividends?
MRK pays a dividend yield of 2.86%, while REGN pays a dividend yield of 0.61%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →